The Legal Intelligencer (2/11, Elliot-Engel) reports, “A month before a pharmaceutical class action was set for trial, a Philadelphia judge decertified the class of users of an epilepsy and neuralgia drug seeking reimbursement from the drug’s maker after being prescribed the drug for uses not approved by federal regulators” granting “a pharmaceutical company defendant’s motion for class decertification in Clark v. Pfizer Monday.” The judge said, “Since some class members have benefited from the use of Neurontin and other class members have not benefited, individual questions of fact are presented making the case unsuitable for class resolution.”
From the American Association for Justice news release.
